Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
David R. Gandara(University of California, Davis), David S. Shames(Gene Therapy Laboratory), David Fabrizio(Foundation Medicine (United States)), Craig Cummings, Christine M. Malboeuf(Foundation Medicine (United States)), Doron Lipson(Genomics (United Kingdom)), Lukas C. Amler(PCR Oncology), Achim Rittmeyer(Unknown), Erica Schleifman(Marker Gene Technologies (United States)), Geoff Otto(Foundation Medicine (United States)), Tony Mok(Chinese University of Hong Kong), Louis Fehrenbacher(Kaiser Permanente Vallejo Medical Center), Alan Sandler(Chinese University of Hong Kong), Wei Zou, Daniel S. Lieber(Foundation Medicine (United States)), Yan Li(Academy of Military Medical Sciences), Sarah Paul, Priti S. Hegde(Foundation Medicine (United States)), Marcus Ballinger, Jacob Silterra(Foundation Medicine (United States)), Todd Riehl, Marcin Kowanetz
Cited by 1,194
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Nuclear ribosomal internal transcribed spacer (ITS) region as a universal DNA barcode marker for <i>Fungi</i>
|Proceedings of the National Academy of Sciences|2012|5.1k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k